Last Updated on September 23, 2021 by The Health Master
The company has acquired a facility in Mehsana, Gujarat and will invest Rs. 30 crore in cephalosporin plant including capacity expansion and modernisation of the facility and to fund the acquisition and capex from internal accruals.
The company expects commercial operations from March 2022. The plant is expected to contribute sales of around Rs. 150 crore in the next 3 years. The plant will cater to all the cephalosporin products i.e. tablet, capsule, dry syrup and injectable.
Cephalosporin is a bactericidal, broad-spectrum, and ß-lactam antibiotic originally derived from fungus acremonium, which is used to treat bacterial infections such as pneumonia, skin infections, ear infection, strep throat, staph infections, tonsillitis, bronchitis and others.
The acquired facility in Mehsana, Gujarat has been designed as per the PIC’s and European Region. Company is in the process of applying for WHO GMP Certifications for the facility and expects to receive the same by December 2021.
Company is planning to manufacture 20 plus cephalosporin products and to start product registration soon for the domestic and exports market.
The cephalosporin products including cefalexin oral suspension BP, clavulanate tablets, cefixime capsules, cefuroxime axetil tablets among others and also looks to export in African, Latin America and Southeast Asia markets and expand to other markets after necessary approvals.
Mahendra Patel, managing director, Lincoln Pharmaceuticals Limited, said, “The entire expansion for cephalosporin products will be funded from internal accruals. The company has earmarked total investment of around Rs. 30 crore for this expansion.
Company expects commercial production of the cephalosporin products by March 2022. In the next 3 years, the facility is expected to contribute sales of around Rs. 150 crore from domestic markets as well as exports.”